Viatris Inc. (VTRS) Business Profile

What it does

Viatris is a global healthcare company that develops, makes and sells medicines. Its portfolio includes branded drugs, generic versions of branded medicines, and more complex generics such as inhaled treatments and injections. Generic drugs are therapeutically equivalent versions of brand drugs and generally become available after patents and other exclusivities expire.

Its medicines cover a range of conditions, including cardiovascular disease, cancer and infectious diseases. Examples include Lipitor and Lyrica among its established brands, Wixela Inhub, a generic version of the inhaled drug Advair Diskus, and an iron sucrose injection for certain patients with anemia. Viatris also provides services such as diagnostic clinics, educational seminars and digital tools to help patients manage their health.

The company sells through customers including pharmacies, wholesalers, governments and hospitals. It also works with other pharmaceutical companies on the development, manufacture and sale of medicines. Its products reach patients across more than 165 countries and territories, and the company supplies medicines to approximately 1 billion patients around the world each year.

Founded in 2020, Viatris is headquartered in Pittsburgh. Scott A. Smith is its chief executive. The company has more than 30,000 employees and operates manufacturing, packaging and distribution sites around the world.

How it makes money

Viatris earns most directly from selling branded and generic medicines across its geographic markets. It reported total revenues of $14.30 billion in 2025 and $3.75 billion in the third quarter of 2026.

The company reports four geographic segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets primarily covers North America and Europe; JANZ comprises Japan, Australia and New Zealand. Each segment sells a portfolio of branded and generic products rather than representing a single drug category.

Branded medicines can be protected by patents or other exclusivity rights. Viatris also sells branded generics: off-patent products marketed under proprietary names. Brands and branded generics are more sensitive to promotion than unbranded generics, so they receive much of the company’s product-level marketing attention. Generic medicines are generally sold in higher volumes at lower margins than branded drugs in many high-income countries.

Sales of existing medicines continue over time, while new product launches add to the portfolio. Generic products, particularly in the U.S., generally contribute most to revenues and gross margins around launch, especially when competition is limited. Additional competitors generally reduce the affected products’ prices and volumes. Outside the U.S., government price reductions and competitive tenders can also affect sales and profit.

Viatris sometimes works with partners under licensing and other commercial agreements. These arrangements can share development, manufacturing and commercialization costs and risks, but usually also require the company to share future profits. Viatris uses its existing regulatory, manufacturing and commercial infrastructure to bring both its own and partners’ products to market.

Customers and how it sells

Viatris sells to retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments and institutions such as hospitals. Its sales and marketing approach varies by product, location and customer channel. Brand and branded generic products receive much of its product-level marketing activity.

AmeriSourceBergen Corporation accounted for 11.0% of revenue in FY2025. Viatris also names Cencora, McKesson and Cardinal Health among its largest customers. The company serves patients through channels that include retail pharmacies, institutions and wholesalers, as well as e-commerce and private hospitals in Greater China.

Viatris manages its business geographically. Developed Markets primarily includes North America and Europe. Greater China comprises mainland China, Taiwan and Hong Kong, while JANZ covers Japan, Australia and New Zealand. Emerging Markets spans developing and emerging economies across Asia, Africa, Eastern Europe, Latin America and the Middle East, and includes the company’s antiretroviral franchise.

For the year ended December 31, 2025, North American net sales totaled approximately $3.39 billion and European net sales totaled approximately $5.12 billion. In the third quarter of 2026, Greater China net sales grew approximately 10% versus the prior year; Viatris said policy changes had begun to moderate growth, particularly in hospitals.

Suppliers and costs

Viatris makes active pharmaceutical ingredients and finished medicines through a combination of its own operations and external manufacturers. After selling its active ingredient business in India, it retained some related research capabilities and has a manufacturing and supply agreement with the buyer, alongside agreements with other manufacturers. The company says certain third-party suppliers produce a substantial portion of its active ingredients and products.

Viatris owns 27 manufacturing, packaging, and distribution sites worldwide. Its significant manufacturing, packaging, warehousing and distribution activities are primarily in the U.S., Puerto Rico, Singapore, India, Australia, China and certain European Union countries. Facilities and suppliers are subject to regulatory inspections and manufacturing requirements.

Costs include manufacturing and supply, research and development, sales and marketing, regulatory compliance and litigation over patents or exclusivities. Developing and securing approval for medicines requires substantial resources; complex generics can be more difficult, costly and time-consuming to bring to market than commodity generics.

Following its strategic review, Viatris expects restructuring charges of between $700 million and $850 million and potential savings of between $600 million and $700 million once the committed activities are fully implemented. The company expects to complete the activities, associated costs and savings primarily over the next three years.

Competitive position

Viatris competes in branded and generic pharmaceuticals across multiple countries and therapeutic areas. Specific competing companies are not identified. Competition depends on factors including product price, timely regulatory approval, manufacturing capability, product quality, marketing, portfolio size and customer service.

Generic medicines compete with branded equivalents and other generics. Viatris says additional generic competition generally has a negative effect on the volume and pricing of affected products. In some markets outside the U.S., manufacturers bid for priority placement under tender systems, often proposing lower prices to win. Branded products can face substantial and rapid sales declines when exclusivity expires and generic versions enter the market.

The company’s complex generics include inhaled medicines and injections. Obtaining approval for complex generics is often more difficult, costly and time-consuming than for commodity generics. Viatris also has a global manufacturing and commercial network and works with partners seeking access to its infrastructure.

Our reading: The manufacturing, regulatory and distribution network provides a meaningful competitive resource because it supports products across many markets, although it does not prevent price competition. Our reading: Complex-product expertise and patent protection can create product-specific defenses, but their strength varies with approvals, exclusivity and the arrival of competitors.

Growth opportunities

Viatris is seeking growth from product launches, a shift toward more complex generics and an expanding portfolio of innovative medicines. It also uses licensing and acquisitions to add products and development programs. Its stated strategy includes strengthening established brands and improving supply continuity.

In October, Viatris launched Gwyn Lo, a low-dose contraceptive patch, in the U.S. It also received U.S. approval for Ryzumvi to treat presbyopia and regulatory approval for Wakix in Japan. The company is preparing for a potential launch of fast-acting meloxicam for pain if it receives approval. Viatris has expanded estradiol patch capacity through operational changes and expects further manufacturing and packaging investment.

The company is advancing selatogrel and cenerimod, with study results for both expected in the first half of 2027. It has also secured first-to-file status for Wegovy semaglutide tablets and is preparing to launch a once-monthly aripiprazole injection in the U.S., for which it was the first to secure final FDA approval.

Viatris has agreed to acquire Pacira BioSciences. The proposed transaction would add the patent-protected U.S. medicines EXPAREL and ZILRETTA; Viatris expected the transaction to close before the end of November. Separately, the company expects its restructuring program to generate savings once fully implemented.

Structural risks

• Manufacturing and supply: The FDA issued a warning letter and import alert for Viatris’ Indore facility, affecting 11 products that will not be accepted into the U.S. until the warning letter is lifted. Viatris suspended manufacturing at Nashik in October while remediation continued. It expected supply disruptions to affect fourth-quarter revenue by approximately $100 million.
• Competition and pricing: Additional generic competition generally reduces prices and volumes. Government price reductions and tender systems can also affect sales and profitability, while branded products can lose sales rapidly after exclusivity expires.
• Development and regulation: New medicines require costly, unpredictable approvals. Delays or failures to obtain and maintain approvals can affect product revenue, and products that are approved may not achieve expected market acceptance.
• Strategy and transactions: Viatris may not achieve the intended benefits of its strategic review, restructuring or acquisitions. Integration can consume resources, divert employee attention and involve restructuring costs.
• International operations: Tariffs, trade restrictions, domestic sourcing requirements, exchange-rate movements and changes in healthcare policies can affect the business. Viatris has also identified variability in the readiness and enforcement of China’s procurement policy across provinces.

Bottom line

Our reading

Viatris combines a broad established-medicines business with a push into complex generics and innovative products, using a global manufacturing and commercial network to reach customers. [item1] Its ability to sustain that model depends on reliable supply and new launches as generic competition, regulation and government pricing actions affect existing products. [item7] The Nashik suspension and proposed Pacira acquisition put supply remediation and execution of the product strategy in focus. [call_prepared]